Summary
Introduction
It has long been known (Peters & Man, 1950 ) that elevated plasma concentrations of cholesterol are commonly found in hypothyroidism. The increase in cholesterol correlates with that in thyroidstimulating hormone (Kutty, Bryant & Farid, 1978) . Triglyceride concentrations may be normal or increased (Kutty et al., 1978) . Although most of the hyperlipoproteinaemias (Beaumont, Carlson, Cooper, Fejfar, Fredrickson & Strasser, 1970) can occur in hypothyroidism, the most common finding is an increase in the main cholesterol-transporting protein, low-density lipoprotein (LDL) (Rossner & Rosenqvist, 1974) . Elevated lipid and lipoprotein concentrations usually return to normal on hormone-substitution therapy (Walton, Campbell & Tonks, 1965a; Rossner & Rosenqvist, 1974) , confirming that the abnormalities result from thyroid insufficiency.
The major lipoprotein classes are heterogeneous and the technique of density-gradient ultracentrifugation (Lindgren, Jensen & Hatch, 1972) can be used to isolate subfractions from very-lowdensity lipoproteins (VLDL) and LDL. There is good evidence (Eisenberg, Bilheimer, Levy & Lmdgren, 1973; Sigurdsson, Nicoll & Lewis, 1975; Ballantyne, Ballantyne, Olsson, Rossner & Carlson, 1977) that the large VLDL particles (S, > 100) are metabolized to progressively smaller VLDL particles under the action of lipoprotein lipase. This leads to formation of particles intermediate in density between VLDL and LDL, which correspond mainly to LDL of S, 10.4-20. These are then converted into the major LDL component of S, 5.7-12 (Eisenberg et al., 1973; Eisenberg & Levy, 1975) . It is generally assumed that in turn these LDL particles are converted into small LDL particles (S, 3.5-6.5).
The present study was therefore undertaken to determine the protein and lipid composition of LDL subfractions of S, 10.4-20, 5.7-12 and 3.5-6 .5 in nine patients with primary hypothyroidism both before and after 3 months of hormonereplacement therapy to determine which subfraction was most affected by the action of thyroid hormone. Analysis was also made of VLDL subfractions of S, > 100, 60-100 and 20-60 in four of the patients.
Materials and methods

Patients
Nine consecutive new patients (eight female, one male) with primary hypothyroidism were studied.
All had the typical clinical features of the disorder and the diagnosis was confirmed by estimation of serum concentrations of thyroxine (T4) and triiodothyronine (T3) (Challand, R a t c u e & Ratcliffe, 1975) and of thyroid-stimulating hormone (TSH) (Hall, Amos & Ormston, 1971) (Table 1) . None had been previously investigated for disordered thyroid function. None showed overt clinical or laboratory evidence of other disorders, e.g. liver or renal disease. In particular, no patient had evidence of disorders which are commonly associated with hyperlipidaemia, such as diabetes or excess intake of alcohol, or had a family history of hyperlipidaemia or premature vascular disease.
After an overnight fast 50 ml of blood was removed. A portion (10 ml) was allowed to clot and serum separated for estimation of T3, T4 and TSH. The remaining blood was collected into potassium EDTA (5 mmol/l final concentration) and plasma separated for estimation of lipoproteins. Samples were stored at 4OC and analysed within 24 h of removal.
The patients were treated with L-thyroxine initially in a dose of 50 pgfday and then increasing by 50 pglday at monthly intervals until each patient was judged to be euthyroid by normal TSH concentration and by clinical criteria (Table 1) . Total LDL, VLDL and HDL and also LDL subfractions from all patients were analysed both before and after 3 months of therapy. VLDL subfractions from four of the patients (nos. 1-4) were also analysed at both times.
Methods
Analysis of VLDL, LDL and HDL. Plasma was centrifuged for 16 h at density 1.006 kg/l in a Prepspin 50 Ultracentrifuge (MSE Ltd, Crawley, 
Results
Initially, six of the patients had type IIa hyperlipoproteinaemia, one had type IIb hyperlipoproteinaemia and two had a normal pattern (Table 2) . Type 111 hyperlipoproteinaemia, which can occur in association with hypothyroidism (Lasser, Burns & Solar, 1974) , was excluded by a normal ratio of VLDL-cholesterol to total triglyceride and by the absence of a 'floating beta' band on electrophoresis of plasma or the top fraction isolated after ultracentrifugation at density 1.006 kg/l. After 3 months three patients had type IIa hyperlipoproteinaemia and six had normal lipoproteincholesterol concentrations. Both the elevated mean total and LDLcholesterol concentrations showed significant falls on thyroxine replacement ( Table 2) . The changes did not correlate with the rise in serum thyroxine concentration. The fall in total triglyceride can probably be ascribed mainly to a fall in LDL-triglyceride. VLDL-and HDL-cholesterol concentrations were initially normal and did not change on therapy. Table 3 gives the lipid and protein composition of the three LDL subfractions before and after therapy. The incomplete recovery of cholesterol can be at least partly ascribed to differences in the methods used to estimate cholesterol in the subfractions and in the whole LDL class. Thyroxine therapy exerted its main effect on the LDL subfraction of largest size (S, 10.4-20) with highly significant falls in both lipids and proteins. The decreases in the major LDL subfraction (S, 5.7-12) were not so marked and in LDL of S, 3.5-6.5 they were not statistically significant. VLDL subfractions were isolated in four of the nine patients. The only major change on therapy was an increase in the concentration of triglyceride in the subfractions (Table 4) .
Discussion
In this study the patients acted as their own 'controls', since they were studied both before and after hormone replacement. Some comparison can also be made with results obtained (Stromberg, Ballantyne, Ballantyne, Third & Bedford, 1977) on a group of normal subjects with the reservations that there are differences in age, sex and body weight between the two groups. In the untreated patients with hypothyroidism LDL of S, 10.4-20 and S, 5.7-12 contained increased concentrations of cholesterol, triglyceride and apoB, whereas only cholesterol was increased in LDL of S, 3.5-6.5. The composition of VLDL subfractions was less affected and only in the subfraction of smallest size (S, 20-60) was the cholesterol concentration increased. After 3 months' thyroxine therapy the composition of both LDL and VLDL subfractions was similar to that of normal subjects.
When the present study was undertaken, it was expected that abnormalities would be found in the VLDL spectrum in hypothyroidism. Rossner & Rosenqvist (1974) found an increase in the concentration of VLDL-cholesterol but not triglyceride in three of seven patients and the mean concentration of cholesterol fell on therapy. From studies on four patients on high and low fat diets O'Hara, presented evidence that thyroid hormone deficiency appeared to affect the whole VLDL spectrum and ascribed this to an influence on lipoprotein lipase (Porte, O'Hara & Williams, 1966) . However, our series of patients with hypothyroidism show relatively little derangement in VLDL. Increased concentrations of VLDL-cholesterol were found in only one of the present nine subjects and in one of a further four patients studied before but not on therapy. Thyroxine replacement did not significantly affect the concentration of VLDL-cholesterol. In the four patients in whom subfractions of VLDL were prepared the only abnormality in the untreated state was an increased concentration of cholesterol in VLDL of S, 20-60. The fall in this on therapy was not significant, but a significant rise did occur in the concentration of triglyceride leading to a normal cholesterol : triglyceride ratio.
Before therapy the most marked increase was found in the LDL subfraction of largest size (S, 10.4-20) , and this was corrected by thyroxine replacement. However, no change occurred in the ratio of cholesterol : triglyceride on therapy, suggesting that thyroxine decreases the number of particles rather than alters the composition of individual particles. Most lipoprotein of intermediate density, formed by sequential catabolism of VLDL by lipoprotein lipase, is found in the LDL subfraction of S, 10.4-20, although some may also separate in the VLDL subfraction of S, 12-20 (Eisenberg et al., 1973) . This intermediate-density lipoprotein is relatively resistant to subsequent catabolism by extrahepatic lipoprotein lipase and it is probably converted into the main LDL component (S, 5-7-12) by a mechanism different from that involved in its formation (Eisenberg et al., 1973; Eisenberg 8c Levy, 1975) , possibly under the action of a hepatic lipase. The findings of the present study provide good evidence that thyroxine plays an important role in mediating the conversion of intermediatedensity lipoprotein into LDL, perhaps by an effect on the converting enzyme.
Abnormalities were also found in the composition of LDL of S, 5.7-12, the major transport medium for cholesterol and apoB, the concentrations of which fell after thyroxine replacement. This is consistent with and extends reports of abnormal cholesterol and apoB metabolism in hypothyroidism. In a definitive study, Miettinen (1968) followed the faecal excretion of end products of cholesterol metabolism after intravenous injection of [3Hlcholesterol in three patients before and after therapy. The fall in serum cholesterol induced by thyroid hormone was associated with a marked increase in excretion of neutral steroids derived from circulating cholesterol, and with a smaller increase in the output of bile acids. The metabolism of the protein component of LDL, which is mainly apoB, was studied in vivo by Walton, Scott, Dykes & Davies (1965b) after intravenous injection of 1311-labelled LDL (probably contaminated with some VLDL). They found that the rate of LDLprotein catabolism was impaired, but returned to normal on therapy.
It is concluded that in our series of patients with hypothyroidism, the major defect in lipoprotein metabolism is impaired conversion of IDL into LDL, although other abnormalities also occur in the metabolism of VLDL and of LDL. The defects can be rectified by thyroid hormone replacement.
